Association between green tea-based chemoprevention and epithelial–mesenchymal transition: current understanding and future perspectives

Le résumé fourni par la source

Premalignant lesions provide a crucial window of opportunity for cancer chemoprevention. Green tea, particularly its major catechin, epigallocatechin-3-gallate (EGCG), has demonstrated potential as a chemopreventive agent. Notably, a green tea ointment (Sinecatechins, or Veregen®) is the first and only botanical drug derived from green tea approved by the U.S. Food and Drug Administration for the treatment of HPV-related epithelial lesions. This approval underscores its clinical translational relevance, even though these lesions are caused by HPV types 6 and 11, which are considered low risk for malignancy. This review summarizes current mechanistic and clinical evidence supporting the role of green tea in suppressing the progression of premalignant lesions, with a specific focus on its ability to modulate the epithelial-mesenchymal transition (EMT). We first review the major constituents, bioavailability, and bioactivities of green tea, followed by the role of EMT in various stages of cancer progression, from early carcinogenesis to premalignant progression, and ultimately to cancer invasion and metastasis. EMT as a potential therapeutic as well as chemopreventive target is also discussed. We then summarize the association of the EMT pathway with the chemopreventive effect of green tea on premalignant lesions in several organ systems, including oral, cervical, colorectal, prostate, and skin. Although the existing in vitro, in vivo, and small-scale human studies are encouraging, definitive, large-scale, randomized, and prospective clinical trials that measure EMT-associated biomarkers are necessary to confirm the efficacy of green tea-based interventions as a strategy for managing premalignant lesions and EMT modulation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.